Aprea Therapeutics Expands IP Portfolio for Precision Oncology Programs

What Happened
Aprea Therapeutics, Inc. (APRE) filed a Form 8-K on August 28, 2026 announcing the expansion of its intellectual property portfolio related to its precision oncology programs. The company issued a press release (attached as Exhibit 99.1) describing the update; the filing was signed by President and CEO Oren Gilad, Ph.D.

Key Details

• Filing date: August 28, 2026 (Form 8-K, Item 8.01 Other Events).
• Announcement format: press release attached as Exhibit 99.1 and incorporated by reference.
• Company executive: signed by Oren Gilad, Ph.D., President and Chief Executive Officer.
• Filing also includes standard Exhibit 104 (interactive XBRL cover page).

Why It Matters
An expanded intellectual property portfolio can strengthen Aprea’s protection around its precision oncology assets, potentially enhancing the company’s competitive position and value of its programs. For investors, IP expansion is a non-financial but material development that could affect future partnerships, licensing opportunities, or strategic deal negotiations. The 8-K provides notice of the change but does not disclose financial impacts or specific patent details; investors should review the press release (Exhibit 99.1) and future filings for more substantive information.